ClinicalTrials.gg
CompletedNCT02622321HAVEN 1Updated Jun 24, 2021Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

A Phase 3 interventional study of Emicizumab and rFVIIa in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 44 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-24.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
4th of 22
113 · median 27
Started
2015
the only one that year
Phase 3
11 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [\<] 9 or greater than or equal to [>/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >/= 40 kilograms (kg) at the time of screening
  • Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor ( that is [i.e.], >/= 5 Bethesda Units [BU])
  • Documentation of treatment with episodic or prophylactic bypassing agents for at least the last 24 weeks
  • >/= 6 bleeds in the last 24 weeks prior to screening (if on an episodic bypassing agent regimen) or >/=2 bleeds in the last 24 weeks prior to screening (if on a prophylactic bypassing agent regimen)
  • Adequate hematologic, hepatic and renal function
  • For women who are not or surgically sterile: agreement to remain abstinent or use single or combined highly effective methods

Exclusion criteria

Exclusion Criteria:

  • Participants with inherited or acquired bleeding disorder other than hemophilia A
  • Participants with ongoing (or plan to receive during the study) immune tolerance induction therapy or prophylaxis with Factor VIII (FVIII), with the exception of participants who have received a treatment regimen of FVIII prophylaxis with concurrent bypassing agent prophylaxis
  • Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which antithrombotic treatment is not currently ongoing) or current signs of thromboembolic disease
  • Participants with other conditions (for example [e.g.], certain diseases) that may increase the risk of bleeding or thrombosis
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Known (HIV) infection with cluster of differentiation 4 (CD4) count \< 200 cells per microliter (cells/mcL) within 24 weeks prior to screening
  • Use of systemic immunomodulators (e.g., interferon or rituximab) at enrolment or planned use during the study, with the exception of antiretroviral therapy
  • Participants who are at high risk for thrombotic microangiopathy (TMA; e.g., have a previous medical or family history of TMA), in the investigator's judgment
  • Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the participant's safe participation in and completion of the study or interpretation of the study results
  • Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
  • Receipt of emicizumab in a prior study; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; An investigational drug concurrently
  • Unwillingness to use highly effective methods for the specified duration in the protocol (females only, unless required otherwise by the local health authority)
  • Clinically significant abnormality on screening evaluations or laboratory tests that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant
  • Pregnancy or lactation, or intent to become pregnant during the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Arm A: 1.5 mg/kg Emicizumab QW

    Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.

    Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC

  • Active comparator
    Arm B (Control): No Prophylaxis, Then Emicizumab

    Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.

    Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC

  • Experimental
    Arm C: 1.5 mg/kg Emicizumab QW

    Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.

    Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC

  • Experimental
    Arm D: 1.5 mg/kg Emicizumab QW

    Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.

    Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC

Interventions

  • Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

    Also known as: Hemlibra, RO5534262, RG6013, ACE910

  • DrugrFVIIa

    Participants will continue to receive rFVIIa.

    Also known as: NovoSeven®

  • DrugaPCC

    Participants will continue to receive aPCC.

    Also known as: Factor Eight Inhibitor Bypassing Activity (FEIBA®)

06

What researchers measure

Primary outcomes

  1. Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of treated bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

Secondary outcomes

  1. Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of all bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  2. Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents

    This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks

  3. Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents

    This was an intra-participant comparison of the ABRs for treated bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks

  4. Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of treated joint bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated joint bleeds were defined as treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Bleeds due to surgery/procedure were excluded.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  5. Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents

    This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm C participants who had previously received prophylactic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks

  6. Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents

    This was an intra-participant comparison of the ABRs for treated bleeds in Arm C participants who had previously received bypassing agent prophylaxis during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks

  7. Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of treated spontaneous bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  8. Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of treated target joint bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated target joint bleeds included treated (with coagulation factors) joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  9. Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  10. Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  11. Percentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

  12. Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis

    Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health).

    Time frame: Week 25

  13. Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis

    Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Questionnaire Total Score is the average of the all domain scores and range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Week 25

  14. European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Week 25

  15. EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single utility index value ranging from 1 to 5, where 1 indicates better health state (no problems) and 5 indicates worst health state (confined to bed).

    Time frame: Week 25

  16. Hemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old)

    The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life. Baseline was defined as the last assessment prior to treatment. Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose; baseline for Arm B (Emi) is the same as Week 25 for Arm B (Control).

    Time frame: Baseline and Week 25 (for Arm B (Emi), Study Weeks are relative to first emicizumab dose)

  17. Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

    The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)

  18. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)

  19. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

    Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)

  20. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  21. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  22. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  23. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  24. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  25. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks

  26. Safety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale

    Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated, only data before up-titration is included. aPCC = activated prothrombin complex concentrate; Hypersens.= hypersensitivity

    Time frame: From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)

  27. Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study

    'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.

    Time frame: From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)

  28. Plasma Trough Concentrations of Emicizumab at Specified Timepoints

    Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose.

    Time frame: Pre-dose (0 hour [hr]) on Weeks 1-5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, and 169 (For Arm B (Emi), Study Weeks are relative to first emicizumab dose)

07

Results

Posted Nov 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QW
Started35184911
Received at least one dose of treatment34184911
Completed 24 weeks in the study31184911
Dose up-titrated to 3 mg/kg qw2032
Completed32184811
Not completed3010
Withdrew: Withdrawal by subject2000
Withdrew: Death0010
Withdrew: Physician decision1000

Outcome measures

PrimaryModel-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of treated bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · treated bleeds per year
Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
treated bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis2.9 (1.69 to 5.02)23.3 (12.33 to 43.89)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.13 · 95% CI 0.057 to 0.277
SecondaryModel-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of all bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · all bleeds per year
Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
all bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis5.5 (3.58 to 8.60)28.3 (16.79 to 47.76)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.20 · 95% CI 0.102 to 0.375
SecondaryIntra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents

This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks
Reported as:
Number · all bleeds per year
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents
all bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm A (NIS): Previous Episodic Bypassing Agents
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents4.1 (2.10 to 8.02)37.7 (28.40 to 50.04)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm A (NIS): Previous Episodic Bypassing Agents · Non-Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.11 · 95% CI 0.055 to 0.218
SecondaryIntra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents

This was an intra-participant comparison of the ABRs for treated bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks
Reported as:
Number · treated bleeds per year
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents
treated bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm A (NIS): Previous Episodic Bypassing Agents
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents1.7 (0.71 to 4.06)21.6 (15.40 to 30.22)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm A (NIS): Previous Episodic Bypassing Agents · Non-Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.08 · 95% CI 0.031 to 0.198
SecondaryModel-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of treated joint bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated joint bleeds were defined as treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Bleeds due to surgery/procedure were excluded.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · treated joint bleeds per year
Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
treated joint bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis0.8 (0.26 to 2.20)6.7 (1.99 to 22.42)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · Stratified Wald Test · p = 0.0050 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.11 · 95% CI 0.025 to 0.520
SecondaryIntra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents

This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm C participants who had previously received prophylactic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks
Reported as:
Number · all bleeds per year
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents
all bleeds per yearArm C: 1.5 mg/kg Emicizumab QWArm C (NIS): Previous Prophylactic Bypassing Agents
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents5.5 (2.98 to 10.26)24.3 (18.11 to 32.67)
Statistical analysis
  • Arm C: 1.5 mg/kg Emicizumab QW vs Arm C (NIS): Previous Prophylactic Bypassing Agents · Non-Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.23 · 95% CI 0.119 to 0.435
SecondaryIntra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents

This was an intra-participant comparison of the ABRs for treated bleeds in Arm C participants who had previously received bypassing agent prophylaxis during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks
Reported as:
Number · treated bleeds per year
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents
treated bleeds per yearArm C: 1.5 mg/kg Emicizumab QWArm Cnis: Previous Prophylactic Bypassing Agents
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents3.3 (1.33 to 8.08)15.7 (11.08 to 22.29)
Statistical analysis
  • Arm C: 1.5 mg/kg Emicizumab QW vs Arm Cnis: Previous Prophylactic Bypassing Agents · Non-Stratified Wald Test · p = 0.0003 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.21 · 95% CI 0.089 to 0.486
SecondaryModel-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of treated spontaneous bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · treated spontaneous bleeds per year
Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
treated spontaneous bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis1.3 (0.73 to 2.19)16.8 (9.94 to 28.30)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · Stratified Wald Test · p = <0.0001 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.08 · 95% CI 0.037 to 0.154
SecondaryModel-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of treated target joint bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated target joint bleeds included treated (with coagulation factors) joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · treated target joint bleeds per year
Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
treated target joint bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis0.1 (0.03 to 0.58)3.0 (0.96 to 9.13)
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · Stratified Wald Test · p = 0.0002 (Statistical significance was controlled at a two-sided alpha level of 0.05 based on a Wald testing procedure.) · Abr ratio: 0.05 · 95% CI 0.009 to 0.227
SecondaryMean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Mean · bleeds per year
Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Treated Bleeds3.5 (0.83 to 9.46)26.2 (17.17 to 38.37)
All Bleeds6.3 (2.37 to 13.45)30.8 (20.89 to 43.76)
Treated Spontaneous Bleeds1.5 (0.11 to 6.42)18.1 (10.74 to 28.57)
Treated Joint Bleeds1.0 (0.03 to 5.57)8.1 (3.55 to 15.95)
Treated Target Joint Bleeds0.4 (0.00 to 4.48)6.2 (2.32 to 13.34)
SecondaryMedian Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Median · bleeds per year
Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Treated Bleeds0.0 (0.00 to 3.73)18.8 (12.97 to 35.08)
All Bleeds2.0 (0.00 to 9.87)30.2 (18.26 to 39.37)
Treated Spontaneous Bleeds0.0 (0.00 to 3.28)15.2 (6.64 to 30.44)
Treated Joint Bleeds0.0 (0.00 to 0.00)1.0 (0.00 to 14.44)
Treated Target Joint Bleeds0.0 (0.00 to 0.00)1.0 (0.00 to 6.52)
SecondaryPercentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis

Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
Percentage of participantsArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Treated Bleeds62.9 (44.9 to 78.5)5.6 (0.1 to 27.3)
All Bleeds37.1 (21.5 to 55.1)5.6 (0.1 to 27.3)
Treated Spontaneous Bleeds68.6 (50.7 to 83.1)11.1 (1.4 to 34.7)
Treated Joint Bleeds85.7 (69.7 to 95.2)50.0 (26.0 to 74.0)
Treated Target Joint Bleeds94.3 (80.8 to 99.3)50.0 (26.0 to 74.0)
SecondaryHemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis

Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health).

Time frame:
Week 25
Reported as:
Mean · score on a scale
Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis
score on a scaleArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis30.19 ± 26.5957.14 ± 23.35
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · ANCOVA · p = 0.0029 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Adjusted mean difference: 21.55 · 95% CI 7.89 to 35.22
SecondaryHaem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis

Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Questionnaire Total Score is the average of the all domain scores and range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Week 25
Reported as:
Mean · score on a scale
Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis
score on a scaleArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis26.465 ± 18.66647.504 ± 17.435
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · ANCOVA · p = 0.0019 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Adjusted mean difference: 14.01 · 95% CI 5.56 to 22.45
SecondaryEuropean Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Week 25
Reported as:
Mean · score on a scale
European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis
score on a scaleArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis83.8 ± 12.976.4 ± 15.7
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · ANCOVA · p = 0.0171 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Adjusted mean difference: -9.72 · 95% CI -17.62 to -1.82
SecondaryEQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single utility index value ranging from 1 to 5, where 1 indicates better health state (no problems) and 5 indicates worst health state (confined to bed).

Time frame:
Week 25
Reported as:
Mean · score on a scale
EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis
score on a scaleArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis
EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis0.83 ± 0.220.60 ± 0.35
Statistical analysis
  • Arm A: 1.5 mg/kg Emicizumab QW vs Arm B (Control): No Prophylaxis · ANCOVA · p = 0.0014 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Adjusted mean difference: -0.16 · 95% CI -0.25 to -0.07
SecondaryHemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old)

The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life. Baseline was defined as the last assessment prior to treatment. Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose; baseline for Arm B (Emi) is the same as Week 25 for Arm B (Control).

Time frame:
Baseline and Week 25 (for Arm B (Emi), Study Weeks are relative to first emicizumab dose)
Reported as:
Mean · units on a scale
Hemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old)
units on a scaleArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No ProphylaxisArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QW
Baseline34.643 ± 22.72837.143 ± 12.12230.000 ± 14.14230.714 ± 15.625
Week 2533.095 ± 17.55930.000 ± 14.14212.143 ± 7.07119.286 ± 14.507
SecondaryLong-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Reported as:
Number · bleeds per year
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWAll Participants: 1.5 mg/kg Emicizumab QW
Treated Bleeds1.9 (1.02 to 3.53)0.6 (0.22 to 1.36)3.2 (1.51 to 6.65)1.5 (0.20 to 11.72)2.4 (1.50 to 3.82)
All Bleeds3.5 (2.11 to 5.74)1.3 (0.66 to 2.39)4.3 (2.43 to 7.77)2.3 (0.79 to 6.77)3.6 (2.55 to 5.13)
Treated Spontaneous Bleeds0.6 (0.33 to 1.26)0.1 (0.06 to 0.29)2.1 (0.89 to 4.80)0.8 (0.07 to 9.16)1.3 (0.76 to 2.18)
Treated Joint Bleeds0.5 (0.16 to 1.69)0.1 (0.04 to 0.31)0.4 (0.14 to 0.96)0.4 (0.05 to 3.41)0.4 (0.21 to 0.82)
Treated Target Joint Bleeds0.1 (0.01 to 0.31)0.01 (0.01 to 0.18)0.3 (0.09 to 0.84)0.3 (0.04 to 2.36)0.2 (0.10 to 0.57)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Reported as:
Mean · bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWAll Participants: 1.5 mg/kg Emicizumab QW
Treated Bleeds2.9 (0.58 to 8.63)0.6 (0.00 to 4.85)3.3 (0.77 to 9.28)1.6 (0.14 to 6.61)2.6 (0.46 to 8.16)
All Bleeds4.8 (1.49 to 11.33)1.3 (0.07 to 6.11)4.6 (1.40 to 11.09)2.5 (0.42 to 8.02)3.9 (1.05 to 10.13)
Treated Spontaneous Bleeds1.2 (0.06 to 5.99)0.2 (0.00 to 4.01)2.2 (0.32 to 7.59)0.9 (0.01 to 5.33)1.5 (0.10 to 6.35)
Treated Joint Bleeds0.9 (0.02 to 5.42)0.1 (0.00 to 3.95)0.4 (0.00 to 4.53)0.4 (0.00 to 4.56)0.5 (0.00 to 4.73)
Treated Target Joint Bleeds0.4 (0.00 to 4.44)0.1 (0.00 to 3.79)0.3 (0.00 to 4.35)0.4 (0.00 to 4.40)0.3 (0.00 to 4.30)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.

Time frame:
From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Reported as:
Median · bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
bleeds per yearArm A: 1.5 mg/kg Emicizumab QWArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWAll Participants: 1.5 mg/kg Emicizumab QW
Treated Bleeds0.3 (0.00 to 2.05)0.0 (0.00 to 0.48)0.0 (0.00 to 1.13)0.0 (0.00 to 0.67)0.0 (0.00 to 1.09)
All Bleeds1.9 (0.22 to 5.13)0.5 (0.00 to 2.18)0.6 (0.00 to 2.25)0.5 (0.00 to 4.41)0.6 (0.00 to 3.34)
Treated Spontaneous Bleeds0.0 (0.00 to 0.87)0.0 (0.00 to 0.24)0.0 (0.00 to 0.47)0.0 (0.00 to 0.00)0.0 (0.00 to 0.51)
Treated Joint Bleeds0.0 (0.00 to 0.24)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Treated Target Joint Bleeds0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Mean · treated bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
treated bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks3.9 (1.05 to 10.12)
13 to 24 Weeks2.2 (0.31 to 7.53)
25 to 36 Weeks0.9 (0.01 to 5.31)
37 to 48 Weeks0.3 (0.00 to 4.38)
49 to 60 Weeks0.4 (0.00 to 4.56)
61 to 72 Weeks0.5 (0.00 to 4.73)
73 to 84 Weeks0.6 (0.00 to 4.80)
85 to 96 Weeks0.4 (0.00 to 4.46)
97 to 108 Weeks0.5 (0.00 to 4.71)
109 to 120 Weeks0.0 (NA to 3.69)
121 to 132 Weeks0.4 (0.00 to 4.48)
133 to 144 Weeks0.5 (0.00 to 4.62)
145 to 156 Weeks0.4 (0.00 to 4.53)
157 to 168 Weeks0.2 (0.00 to 4.01)
169 to 180 Weeks0.2 (0.00 to 4.08)
181 to 192 Weeks0.0 (NA to 3.69)
193 to 204 Weeks0.0 (NA to 3.69)
205 to 216 Weeks0.0 (NA to 3.69)
217 to 228 Weeks0.0 (NA to 3.69)
229 to 240 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Median · treated bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
treated bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks0.0 (0.00 to 4.35)
13 to 24 Weeks0.0 (0.00 to 0.00)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Mean · all bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
all bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks6.2 (2.35 to 13.40)
13 to 24 Weeks3.4 (0.78 to 9.29)
25 to 36 Weeks1.5 (0.11 to 6.40)
37 to 48 Weeks1.4 (0.09 to 6.29)
49 to 60 Weeks1.1 (0.04 to 5.74)
61 to 72 Weeks1.0 (0.02 to 5.53)
73 to 84 Weeks1.3 (0.07 to 6.12)
85 to 96 Weeks1.0 (0.02 to 5.56)
97 to 108 Weeks1.2 (0.05 to 5.86)
109 to 120 Weeks0.9 (0.01 to 5.34)
121 to 132 Weeks0.8 (0.01 to 5.20)
133 to 144 Weeks0.5 (0.00 to 4.62)
145 to 156 Weeks0.8 (0.01 to 5.29)
157 to 168 Weeks0.3 (0.00 to 4.31)
169 to 180 Weeks0.8 (0.01 to 5.14)
181 to 192 Weeks0.2 (0.00 to 4.15)
193 to 204 Weeks0.0 (NA to 3.69)
205 to 216 Weeks0.0 (NA to 3.69)
217 to 228 Weeks0.0 (NA to 3.69)
229 to 240 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Median · all bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
all bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks0.0 (0.00 to 8.70)
13 to 24 Weeks0.0 (0.00 to 4.35)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Mean · treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
treated spontaneous bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks2.2 (0.31 to 7.56)
13 to 24 Weeks1.3 (0.06 to 6.04)
25 to 36 Weeks0.4 (0.00 to 4.45)
37 to 48 Weeks0.2 (0.00 to 4.04)
49 to 60 Weeks0.1 (0.00 to 3.96)
61 to 72 Weeks0.2 (0.00 to 4.05)
73 to 84 Weeks0.2 (0.00 to 4.08)
85 to 96 Weeks0.1 (0.00 to 3.92)
97 to 108 Weeks0.3 (0.00 to 4.34)
109 to 120 Weeks0.0 (NA to 3.69)
121 to 132 Weeks0.1 (0.00 to 3.89)
133 to 144 Weeks0.0 (NA to 3.69)
145 to 156 Weeks0.4 (0.00 to 4.53)
157 to 168 Weeks0.2 (0.00 to 4.01)
169 to 180 Weeks0.2 (0.00 to 4.08)
181 to 192 Weeks0.0 (NA to 3.69)
193 to 204 Weeks0.0 (NA to 3.69)
205 to 216 Weeks0.0 (NA to 3.69)
217 to 228 Weeks0.0 (NA to 3.69)
229 to 240 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Reported as:
Median · treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
treated spontaneous bleeds per yearAll Participants: 1.5 mg/kg Emicizumab QW
1 to 12 Weeks0.0 (0.00 to 0.00)
13 to 24 Weeks0.0 (0.00 to 0.00)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
SecondarySafety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale

Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated, only data before up-titration is included. aPCC = activated prothrombin complex concentrate; Hypersens.= hypersensitivity

Time frame:
From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)
Reported as:
Count of participants · Participants
Safety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale
ParticipantsArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No ProphylaxisArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QW
Any Adverse Event (AE)34915469
AE with Fatal Outcome00010
Serious AE104492
AE Leading to Withdrawal from Treatment20010
AE Leading to Dose Mod./Interruption10050
Grade ≥3 AE104373
Related AE1504134
Local Injection Site Reaction90374
Systemic Hypersens./Anaphylac(tic/toid) Reaction00000
Thrombotic Microangiopathy (TMA)10020
TMA Event Related to aPCC and Emicizumab10020
Thromboembolic Event (TE)11110
TE Event Related to aPCC and Emicizumab10010
SecondaryNumber of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study

'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.

Time frame:
From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)
Reported as:
Count of participants · Participants
Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study
ParticipantsArm A: 1.5 mg/kg Emicizumab QWArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QW
Total ADA Negative (Neg+Neg Unaffected)33184711
ADA Negative, Negative33174611
ADA Negative, Negative (Treatment Unaffected)0110
Total ADA Positive (Boosted + Induced)0020
ADA Positive, Positive (Treatment Boosted)0000
ADA Positive, Positive (Treatment Induced)0020
ADA Positive with Neutralizing ADAs0020
SecondaryPlasma Trough Concentrations of Emicizumab at Specified Timepoints

Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose.

Time frame:
Pre-dose (0 hour [hr]) on Weeks 1-5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, and 169 (For Arm B (Emi), Study Weeks are relative to first emicizumab dose)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Plasma Trough Concentrations of Emicizumab at Specified Timepoints
micrograms per milliliter (mcg/mL)Arm A: 1.5 mg/kg Emicizumab QWArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWAll Participants: 1.5 mg/kg Emicizumab QW
Week 1NA ± NANA ± NANA ± NANA ± NANA ± NA
Week 216.2 ± 4.421.7 ± 10.615.8 ± 5.518.3 ± 6.517.1 ± 6.6
Week 331.6 ± 7.332.3 ± 10.431.7 ± 8.332.7 ± 13.031.9 ± 8.8
Week 443.8 ± 12.244.6 ± 18.644.7 ± 11.549.0 ± 13.544.9 ± 13.2
Week 553.5 ± 15.152.2 ± 14.254.0 ± 13.259.1 ± 14.654.1 ± 14.0
Week 752.8 ± 16.253.3 ± 18.053.6 ± 14.354.9 ± 9.253.4 ± 14.9
Week 950.4 ± 12.448.9 ± 16.752.6 ± 15.753.7 ± 13.851.5 ± 14.7
Week 1349.3 ± 13.445.2 ± 16.252.6 ± 15.053.4 ± 14.050.5 ± 14.7
Week 1750.7 ± 15.046.5 ± 17.451.2 ± 14.957.5 ± 16.951.0 ± 15.6
Week 2152.6 ± 17.444.5 ± 15.451.6 ± 17.155.0 ± 13.751.1 ± 16.6
Week 2554.6 ± 19.145.8 ± 18.650.4 ± 16.852.8 ± 14.151.2 ± 17.6
Week 3350.7 ± 17.248.1 ± 21.154.8 ± 16.757.1 ± 15.252.7 ± 17.5
Week 4145.3 ± 13.749.3 ± 25.954.8 ± 23.463.3 ± 19.452.0 ± 21.6
Week 4948.0 ± 12.354.6 ± 27.656.1 ± 22.255.1 ± 18.753.3 ± 20.5
Week 6152.2 ± 16.351.8 ± 33.460.9 ± 27.753.2 ± 13.856.0 ± 24.8
Week 7355.5 ± 14.945.6 ± 26.262.9 ± 24.951.9 ± 13.057.1 ± 22.0
Week 8556.9 ± 18.342.5 ± 34.456.6 ± 22.750.9 ± 12.554.5 ± 22.7
Week 9753.2 ± 15.234.4 ± 26.454.6 ± 20.053.8 ± 16.951.3 ± 19.9
Week 10949.6 ± 15.932.8 ± 31.447.4 ± 12.449.3 ± 12.846.7 ± 17.6
Week 12153.8 ± 16.336.1 ± 33.646.3 ± 12.553.1 ± 5.048.5 ± 19.7
Week 13350.5 ± 15.948.7 ± 29.449.0 ± 18.552.0 ± NA49.8 ± 18.8
Week 14551.3 ± 16.638.2 ± 19.044.0 ± 21.749.5 ± 10.347.4 ± 17.4
Week 15758.0 ± 16.5—45.5 ± 17.055.4 ± 19.255.3 ± 16.7
Week 16955.0 ± 19.3—43.2 ± 20.250.8 ± NA52.5 ± 18.7

Adverse events

Collected over From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: 1.5 mg/kg Emicizumab QW0/34 (0%)11/34 (32.4%)33/34 (97.1%)
Arm B (Control): No Prophylaxis0/18 (0%)5/18 (27.8%)9/18 (50%)
Arm B (Emi): 1.5 mg/kg Emicizumab QW0/18 (0%)4/18 (22.2%)15/18 (83.3%)
Arm C: 1.5 mg/kg Emicizumab QW1/49 (2%)9/49 (18.4%)42/49 (85.7%)
Arm D: 1.5 mg/kg Emicizumab QW0/11 (0%)2/11 (18.2%)9/11 (81.8%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No ProphylaxisArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QW
HaemarthrosisMusculoskeletal and connective tissue disorders2/342/181/182/490/11
Tooth development disorderGastrointestinal disorders0/340/180/180/491/11
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/340/180/180/491/11
Gastrointestinal haemorrhageGastrointestinal disorders1/341/180/180/490/11
Device related infectionInfections and infestations0/341/180/181/490/11
Urinary tract infectionInfections and infestations0/341/180/180/490/11
HaematuriaRenal and urinary disorders0/341/180/181/490/11
MyalgiaMusculoskeletal and connective tissue disorders0/340/181/180/490/11
HaematomaVascular disorders0/340/181/180/490/11
Large intestine polypGastrointestinal disorders0/340/181/180/490/11
Most frequent other events
Showing 10 of 103
Most frequent other events
EventArm A: 1.5 mg/kg Emicizumab QWArm B (Control): No ProphylaxisArm B (Emi): 1.5 mg/kg Emicizumab QWArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QW
NasopharyngitisInfections and infestations11/342/187/1816/492/11
Injection site reactionGeneral disorders9/340/183/188/494/11
ArthralgiaMusculoskeletal and connective tissue disorders9/340/186/1812/493/11
HeadacheNervous system disorders6/341/184/1813/493/11
Upper respiratory tract infectionInfections and infestations8/342/182/187/492/11
InfluenzaInfections and infestations1/340/182/1810/490/11
ToothacheGastrointestinal disorders4/340/182/182/492/11
Skin abrasionInjury, poisoning and procedural complications1/340/180/180/492/11
Nasal congestionRespiratory, thoracic and mediastinal disorders0/340/180/180/492/11
HypertensionVascular disorders5/340/180/183/492/11

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
Mean35.8 ± 13.937.2 ± 13.725.6 ± 16.839.0 ± 16.131.9 ± 16.2
Age, Customized
Age, Customized(Participants)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
Adolescents (12-17 years)4226032
Adults (18-64 years)3015211076
Elderly (65-84 years)11215
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
Female00000
Male35184911113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
Hispanic or Latino4112118
Not Hispanic or Latino3117371095
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
American Indian or Alaska Native00101
Asian1038021
Native Hawaiian or Other Pacific Islander01001
Black or African American443011
White2110331175
More than one race00000
Unknown or Not Reported00404
Number of Participants by the Number of Bleeds (<9 or ≥9) in the Last 24 Weeks Prior to Study Entry
Number of Participants by the Number of Bleeds (<9 or ≥9) in the Last 24 Weeks Prior to Study Entry(Participants)Arm A: 1.5 mg/kg Emicizumab QWArm B (Control): No Prophylaxis, Then EmicizumabArm C: 1.5 mg/kg Emicizumab QWArm D: 1.5 mg/kg Emicizumab QWTotal
<9 Bleeds11523645
≥9 Bleeds241326568
08

Study locations

44 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90010, United States
  • Santa Monica Oncology Center
    Santa Monica, California 90403, United States
  • University of Colorado Denver, Children's Hospital
    Aurora, Colorado 80045, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Children's Hospital of Michigan; Pediatrics
    Detroit, Michigan 48201, United States
  • Cornell Univ Medical College; Hematology-Oncolog
    New York, New York 10021, United States
  • Oregon Health & Science Uni ; Dept of Pediatrics
    Portland, Oregon 97201, United States
  • Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046
    Hershey, Pennsylvania 17033-0850, United States
  • Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr
    Houston, Texas 77030, United States
  • Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia
    Seattle, Washington 98104, United States
  • Royal Prince Alfred Hospital; Haematology
    Camperdown, New South Wales 2050, Australia
  • The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit
    Melbourne, Victoria 3004, Australia
  • ICIC
    San Jose, 1000, Costa Rica
  • Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique
    Bron, 69677, France
  • CH de Bicetre; Centre de Traitement d' Hemophilie
    Le Kremlin Bicetre, 94275, France
  • Hopital Cardiologique; Hematologie B
    Lille, 59037, France
  • Groupe Hospitalier Necker Enfants Malades
    Paris, 75015, France
  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
    Bonn, 53127, Germany
  • CTC North GmbH & Co. KG am Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • Hämophilie-Zentrum Rhein Main GmbH
    Mörfelden-Walldorf, 64546, Germany
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
    Milano, Lombardia 20122, Italy
  • AOU Careggi; SOD Malattie Emorragiche
    Firenze, Toscana 50134, Italy
  • Nagoya University Hospital
    Aichi, 466-8560, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, 663-8501, Japan
  • St. Marianna University School of Medicine Hospital
    Kanagawa, 216-8511, Japan
  • Hospital of the University of Occupational and Environmental Health,Japan
    Kitakyushu-shi, 807-8556, Japan
  • Nara Medical University Hospital
    Nara, 634-8522, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Auckland City Hospital; Auckland Haemophilia Centre
    Auckland, 1023, New Zealand
  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
    Gdansk, 80-952, Poland
  • SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
    Lublin, 20-081, Poland
  • ALVAMED Lekarskie Gabinety Specjalistyczne
    Poznań, 60-549, Poland
  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
    Warsaw, 02-776, Poland
  • Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center
    Johannesburg, 2193, South Africa
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Hospital Universitario la Fe; Servicio de Hematologia
    Valencia, 46026, Spain
  • National Taiwan Uni Hospital
    Taipei City, 10041, Taiwan
  • Cardiff and Vale NHS Trust
    Cardiff, CF14 4XW, United Kingdom
  • St Thomas' Hospital; Haemostasis & Thromboisis Centre
    London, SE1 7EH, United Kingdom
  • Oxford University Hospitals NHS Trust - Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jimenez-Yuste V. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 Dec 27;6(24):6140-6150. doi: 10.1182/bloodadvances.2022007458. PubMed 35939785 ↗
  • Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10. PubMed 28691557 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Oct 2016, 11 months.

Results were first posted in Nov 2017, 1 year after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2015
First posted
Dec 4, 2015
StartActual
Nov 18, 2015
Primary completionActual
Oct 25, 2016
CompletionActual
Dec 1, 2020
Results first posted
Nov 24, 2017
Last update
Jun 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02622321
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 4, 2015
Start date
Nov 18, 2015
Primary completion
Oct 25, 2016
Completion
Dec 1, 2020
Results posted
Nov 24, 2017
Last update
Jun 24, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion